Board of Directors

David is an experienced public company biotech CEO, board member and biotech investor. He was the CEO of Zealand Pharma A/S (NASDAQ:ZEAL) from 2008 to 2015. Under David’s leadership the company went public on NASDAQ OMX and its lead product, Adlixin®, a GLP-1 receptor agonist for the treatment of type II diabetes, was approved in the US and globally and is now marketed by Sanofi as a monotherapy and in combination with Lantus as Soliqua®. David was also the CEO of Bionor Pharma ASA (OSL:BIONOR) and Akari Therapeutics, Plc (NASDAQ:AKTX), and was the Managing Partner of Sund Capital, ApS, a Nordic healthcare investment fund.

He has earlier served as a faculty member at Columbia University’s College of Physicians and Surgeons in New York City. From 2003 to 2006, David headed healthcare investment at Carrot Capital Healthcare Ventures in New York. David is currently a member of the Board of Directors of TxCell SA (NYSE EURONEXT:TXCL), and was earlier a member of the Boards at Onxeo SA (NYSE EURONEXT:ONXEO) and Promosome, LLC. Dr Solomon studied at Weil Cornell Medicine of Cornell University and its Graduate School of Medical Science where he received his Ph.D.

Iain, was appointed Non-Executive Chairman of Silence Therapeutics plc in April 2019. Iain has over 40 years’ experience in the international life sciences and technology sectors, where he has completed multiple financing transactions, and over 25 years in cross-border management as Chairman and CEO. He has led and participated in six Initial Public Offerings (“IPOs”) and has direct experience of M&A transactions in Europe, the USA and the Pacific Rim. Currently he is Non-Executive Chairman of Redx Pharma plc (LSE), e-Therapeutics plc, and Kazia Therapeutics Limited (ASX & NASDAQ) and was responsible for leading the turnaround of all three companies before appointing new executive management. He is a qualified Chartered Director and former Vice Chairman of the Council of Royal Holloway, London University. Previously, he has held significant roles in multi-national companies including Sandoz, Hoffman La Roche, Reed Business Publishing and Celltech Group plc. He has advised banks and private equity groups on numerous company turnarounds including, as CEO of Quadrant Healthcare (1996-2000), taking the company public and signing numerous collaborations before selling the business to Elan in 2001. As Chairman and CEO at Allergy Therapeutics (2001-2002) he restructured the company prior to its IPO and as Chairman at Silence Therapeutics plc (2004-2010) he turned the business around through M&A and established numerous big pharma collaborations. As Executive Chairman at Ark Therapeutics plc (2010-2015) he successfully restructured the business and disposed of the manufacturing assets and reversed in Premier Veterinary Group.

James Ede-Golightly is chairman of DeepMatter Group Plc, Gulfsands Petroleum Plc, East Balkan Properties Plc and Oxford Advanced Surfaces Ltd and has extensive experience as a non-executive on the boards of AIM-quoted companies with international business interests. James was a founder of ORA Capital Partners in 2006, having previously worked as an analyst at Merrill Lynch Investment Managers and Commerzbank. He is a CFA Charterholder and holds an MA in economics from Cambridge University. In 2012, he was awarded New Chartered Director of the Year by the Institute of Directors.

Alistair brings a wealth of strategic consultancy and business experience. Having trained as an accountant, his early career was in senior management positions with Unilever and John Wood Group PLC. Alistair was a Director of Arthur Young (now Ernst and Young) Management Consultants and PA Consulting Group for over ten years. Alistair previously chaired the Audit and Remuneration committees of AorTech International PLC and Highland Distillers PLC, as well as the Pension Trustee Board. Alistair also served as a Fellow of the Institute of Directors and Institute of Consultants. His key role at Silence is to chair the Audit and Risk Committee.

Dave has over 20 years of US and international business experience in the pharmaceutical and biotechnology industries, having served in executive management and non-executive board roles in multiple US and European private and publicly-traded companies. Dave is presently Principal & CEO of LEMAX LLC. Previously he served as Chief Operating Officer and Chief Financial Officer of Medigene AG, and prior to this as Chief Executive Officer of Sigma Tau Pharmaceuticals, Inc. Dave was also Chief Financial Officer and Executive VP of MorphoSys AG, taking the Company public in 1999 in Germany's first biotech IPO and has held various positions at leading pharma companies including at Hoffman La Roche.

Dr. Steven Romano is a board-certified psychiatrist and seasoned pharmaceutical executive with 25 years of research and development experience across a wide range of therapeutic and disease areas. Dr. Romano currently serves as executive vice president and chief scientific officer at Mallinckrodt Pharmaceuticals where he has responsibility for research and development, regulatory and medical affairs, pharmacovigilance and device engineering. Prior to joining Mallinckrodt, Dr. Romano spent 16 years at Pfizer, Inc. where he held a series of senior R&D and medical roles of increasing responsibility, culminating in his most recent position as SVP, Head, Global Medicines Development, Global Innovative Pharmaceuticals Business. Prior to joining Pfizer, he spent four years at Eli Lilly.